Limits...
Aspirin for the older person: report of a meeting at the Royal Society of Medicine, London, 3rd November 2011.

Armitage J, Cuzick J, Elwood P, Longley M, Perkins A, Spencer K, Turner H, Porch S, Lyness S, Kennedy J, Henderson G - Ecancermedicalscience (2012)

Bottom Line: On November 23rd 2011, the Aspirin Foundation held a meeting at the Royal Society of Medicine in London to review current thinking on the potential role of aspirin in preventing cardiovascular disease and reducing the risk of cancer in older people.The meeting was supported by Bayer Pharma AG and Novacyl.

View Article: PubMed Central - PubMed

Affiliation: Professor of Clinical Trials and Epidemiology, Clinical Trials Surveillance Unit, Oxford.

ABSTRACT
On November 23rd 2011, the Aspirin Foundation held a meeting at the Royal Society of Medicine in London to review current thinking on the potential role of aspirin in preventing cardiovascular disease and reducing the risk of cancer in older people. The meeting was supported by Bayer Pharma AG and Novacyl.

No MeSH data available.


Related in: MedlinePlus

Mortality trends for vascular disease (left) and CHD (right) aged 70–79.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC3298410&req=5

f4-can-6-245: Mortality trends for vascular disease (left) and CHD (right) aged 70–79.

Mentions: The assessment of the potential benefit of aspirin must take into account the changing background incidence of vascular events and alternative interventions. Vascular mortality has declined substantially in many countries among younger adults and both vascular and coronary heart disease among 70–79 year-olds (Figure 1) (data for the over-80s are not sufficiently reliable). Furthermore, primary prevention through treatment with statins and reduction of blood pressure can halve the risk of vascular events, including coronary events, and the risk of stroke.


Aspirin for the older person: report of a meeting at the Royal Society of Medicine, London, 3rd November 2011.

Armitage J, Cuzick J, Elwood P, Longley M, Perkins A, Spencer K, Turner H, Porch S, Lyness S, Kennedy J, Henderson G - Ecancermedicalscience (2012)

Mortality trends for vascular disease (left) and CHD (right) aged 70–79.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC3298410&req=5

f4-can-6-245: Mortality trends for vascular disease (left) and CHD (right) aged 70–79.
Mentions: The assessment of the potential benefit of aspirin must take into account the changing background incidence of vascular events and alternative interventions. Vascular mortality has declined substantially in many countries among younger adults and both vascular and coronary heart disease among 70–79 year-olds (Figure 1) (data for the over-80s are not sufficiently reliable). Furthermore, primary prevention through treatment with statins and reduction of blood pressure can halve the risk of vascular events, including coronary events, and the risk of stroke.

Bottom Line: On November 23rd 2011, the Aspirin Foundation held a meeting at the Royal Society of Medicine in London to review current thinking on the potential role of aspirin in preventing cardiovascular disease and reducing the risk of cancer in older people.The meeting was supported by Bayer Pharma AG and Novacyl.

View Article: PubMed Central - PubMed

Affiliation: Professor of Clinical Trials and Epidemiology, Clinical Trials Surveillance Unit, Oxford.

ABSTRACT
On November 23rd 2011, the Aspirin Foundation held a meeting at the Royal Society of Medicine in London to review current thinking on the potential role of aspirin in preventing cardiovascular disease and reducing the risk of cancer in older people. The meeting was supported by Bayer Pharma AG and Novacyl.

No MeSH data available.


Related in: MedlinePlus